BGI Genomics: Advancing Life Science with Scalable Genomics and Precision Diagnostics

At the core of BGI’s technological capabilities is its self-developed line of ultra-high-throughput sequencers, including the DNBSEQ™ series. These platforms dramatically reduce the cost and increase the scale of DNA sequencing, enabling applications ranging from large-scale population genomics to rare disease diagnostics. BGI also played a prominent role in global COVID-19 response through the development of rapid nucleic acid testing kits and mobile labs deployed worldwide.

BGI’s business spans early cancer detection, reproductive health, infectious disease surveillance, and multi-omics analysis. Its precision medicine platform integrates genome sequencing, transcriptomics, and clinical data to guide treatment plans tailored to individual patients. The company also invests heavily in AI-driven bioinformatics pipelines and clinical annotation engines to support automated diagnosis and research discovery.

BGI maintains deep collaborations with world-class academic institutions including Harvard Medical School and the University of Cambridge. These partnerships focus on translational research in cancer screening, gene therapy, and CRISPR-based functional genomics. Joint studies target early detection biomarkers, scalable clinical validation models, and the safe implementation of advanced gene-editing tools.

Through these academic alliances, BGI aims to close the gap between cutting-edge genetic research and clinical deployment — accelerating the development of globally accessible, data-driven medical solutions. With one of the world’s largest genomics research infrastructures, BGI continues to lead the charge toward a future shaped by genomic intelligence.